Encephalitis: Clinical Trials

36 trials for Encephalitis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

36 completed. 36 Phase 2, 4 Phase 1, 3 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 236Completed 36
Phase 14Completed 4
Phase 33Completed 3

Follow Encephalitis: new trials by email Literature Review of Encephalitis trials Research Report on Encephalitis

Trials (filtered) newest first · largest first

All 36 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Assess the Safety, Reactogenicity, and Immunogenicity of SK Japanese Encephalitis Messenger Ribonucleic Acid (mRNA) Vaccines (GBP560) in Healthy Adults
GBP560-A, GBP560-B, IXIARO - Japanese Encephalitis Virus Disease
Phase 1 / Phase 2CompletedSK Bioscience Co., Ltd.1612025-02-242026-09-11
Immunoadsorption Therapy in Managing NMDAR Antibodies Encephalitis
IA session, Rituximab - Anti-NMDAR Encephalitis
Phase 2CompletedAssistance Publique - Hôpitaux de Paris202021-06-232026-08-10
MCLENA-1: A Clinical Trial for the Assessment of Lenalidomide in Amnestic MCI Patients
Lenalidomide 10 mg, Placebo - Cognitive Impairment, Mild, Cognitive Dysfunction
Phase 2CompletedSt. Joseph's Hospital and Medical Center, Phoenix152020-07-222026-06-10
EG-501 for Cognitive Impairment in Neuropsychiatric SLE (NPSLE): Efficacy and Safety Study
Placebo, EG-501 - Neuropsychiatric Systemic Lupus Erythematosus, Systemic Lupus Erythematosus (SLE)
Phase 2CompletedEvergreen Therapeutics, Inc.1312018-08-232025-12-15
Treatment With Tamoxifen in Cryptococcal Meningitis
Tamoxifen, Amphotericin B, Fluconazole - Meningitis Streptococcal, Hiv
Phase 2CompletedOxford University Clinical Research Unit, Vietnam502017-10-102019-12-02
Safety of Vero Cell - Derived Inactivated Japanese Encephalitis Vaccine (JECEVAX) in Children From 9-24 Months of Age
JEVAX, JECEVAX - Japanese Encephalitis
Phase 2CompletedNational Institute of Hygiene and Epidemiology, Vietnam2202017-06-022018-09-17
IL-2 in Refractory Autoimmune Encephalitis
Proleukin - Encephalitis
Phase 1 / Phase 2CompletedSeoul National University Hospital102016-03-012021-09-29
Safety and Immunogenicity of JECEVAX in Young Children
JEVAX, JECEVAX-1, JECEVAX-0.8 - Japanese Encephalitis
Phase 2CompletedNational Institute of Hygiene and Epidemiology, Vietnam2002015-04-012016-06-28
New Study - Humoral Response to Tick-borne Encephalitis Vaccine in Elderly
FSME-immune - Tick-borne Encephalitis
Phase 2 / Phase 3CompletedSormland County Council, Sweden2502015-01-012021-02-10
Humoral and Cellular Immunity for TBE Vaccination in Allogeneic HSCT Recipients
TBE virus vaccine - Tick Borne Encephalitis
Phase 2CompletedMedical University of Vienna342014-07-012022-02-03
Stem Cell Transplantation In-patient With Neurological Sequelae Due to Encephalitis or Meningitis
Stem cell transplantation - Encephalitis, Meningitis
Phase 1 / Phase 2CompletedVinmec Research Institute of Stem Cell and Gene Technology222014-06-162024-06-06
The Role of Pre-existing Cross-reactive Antibodies in Determining the Efficacy of Vaccination in Humans
Japanese Encephalitis vaccine, Yellow Fever vaccine - Yellow Fever, Encephalitis, Japanese
Phase 2CompletedSingapore General Hospital842013-10-012016-04-20
Humoral Response to Tick-borne Encephalitis Vaccine in Elderly
FSME-immune - Tick-borne Encephalitis
Phase 2 / Phase 3CompletedSormland County Council, Sweden2002011-09-012015-11-18
Safety and Efficacy Study of Intravenous Immunoglobulin to Treat Japanese Encephalitis
Intravenous immunoglobulin [ImmunoRel™ (batch 20081217)] - Japanese Encephalitis
Phase 2CompletedUniversity of Liverpool222009-05-012013-05-21
Safety and Immunogenicity Study of ChimeriVax West Nile Vaccine in Healthy Adults
ChimeriVax-WN02 vaccine, Placebo - West Nile Fever
Phase 2CompletedSanofi Pasteur, a Sanofi Company4792008-10-012015-04-03
Safety and Immunogenicity Study of Eastern Equine Encephalitis (EEE) Vaccine
Inactivated, Dried, TSI-GSD 104, EEE - Eastern Equine Encephalitis
Phase 2CompletedU.S. Army Medical Research and Development Command1382008-06-032019-09-24
Safety and Immunogenicity Study of the Eastern Equine Encephalitis (EEE) Vaccine
Eastern Equine Encephalitis Vaccine, Inactivated, Dried, TSI-GSD 104 - Eastern Equine Encephalitis
Phase 2CompletedU.S. Army Medical Research and Development Command1382008-06-032020-03-17
Immunogenicity and Safety of ChimeriVax™ Japanese Encephalitis Vaccine in Thai Toddlers and Children
Japanese encephalitis vaccine (Day 0) Hepatitis A vaccine (Day 28), Hepatitis A vaccine (Day 0) Japanese encephalitis vaccine (Day 28) - Japanese Encephalitis, Hepatitis A
Phase 2CompletedSanofi Pasteur, a Sanofi Company3002008-03-012014-10-02
Safety and Efficacy Study of ChimeriVax™-JE and JE Inactivated Mouse Brain Vaccine in Children of Descending Age
ChimeriVax™-JE, Japanese Encephalitis Inactivated Mouse Brain Vaccine - Japanese Encephalitis
Phase 2CompletedSanofi962007-01-012012-08-27
Safety and Immunogenicity of ChimeriVax-WN02 West Nile Vaccine in Healthy Adults
ChimeriVax-WN02 Low Dose, ChimeriVax-WN02 Medium Dose, ChimeriVax-WN02 High Dose - West Nile Fever
Phase 2CompletedSanofi Pasteur, a Sanofi Company2082005-12-012016-04-14

Showing 20 of 36. Sign in to see all of them.

Narrower conditions

Encephalitis, Japanese (12)  ·  Encephalitis, Tick-Borne (8)  ·  HIV Infections (4)  ·  Acquired Immunodeficiency Syndrome (3)  ·  Leukoencephalopathy, Progressive Multifocal (3)  ·  Cognitive Dysfunction (2)  ·  Encephalomyelitis, Eastern Equine (2)  ·  Meningitis (2)  ·  Myelitis (2)  ·  West Nile Fever (2)  ·  Yellow Fever (2)  ·  AIDS-Related Opportunistic Infections (1)  ·  Alzheimer Disease (1)  ·  Anti-N-Methyl-D-Aspartate Receptor Encephalitis (1)

Broader conditions

Brain Diseases (36)  ·  Central Nervous System Diseases (36)  ·  Nervous System Diseases (36)  ·  Neuroinflammatory Diseases (36)  ·  Central Nervous System Infections (32)  ·  Infections (32)  ·  Central Nervous System Viral Diseases (29)  ·  RNA Virus Infections (29)  ·  Virus Diseases (29)  ·  Encephalitis, Viral (27)  ·  Infectious Encephalitis (27)  ·  Arbovirus Infections (24)  ·  Encephalitis, Arbovirus (24)  ·  Vector Borne Diseases (24)

Interventions

Vaccines (3)  ·  Desiccation (2)  ·  Japanese Encephalitis Vaccines (2)  ·  Saline Solution (2)  ·  Amphotericin B (1)  ·  Atovaquone (1)  ·  Clarithromycin (1)  ·  Cytarabine (1)  ·  Didanosine (1)  ·  Enfuvirtide (1)  ·  FSME-IMMUN vaccine (1)  ·  Filgrastim (1)  ·  Fluconazole (1)  ·  Hepatitis A Vaccines (1)  ·  Immunoglobulins, Intravenous (1)

Sponsors

Pfizer (5)  ·  Sanofi (5)  ·  National Institute of Allergy and Infectious Diseases (NIAID) (3)  ·  Sanofi Pasteur, a Sanofi Company (3)  ·  National Institute of Hygiene and Epidemiology, Vietnam (2)  ·  Sormland County Council, Sweden (2)  ·  U.S. Army Medical Research and Development Command (2)  ·  Assistance Publique - Hôpitaux de Paris (1)  ·  Evergreen Therapeutics, Inc. (1)  ·  French National Agency for Research on AIDS and Viral Hepatitis (1)  ·  Medical University of Vienna (1)  ·  National Institutes of Health Clinical Center (CC) (1)  ·  Novartis (1)  ·  Oxford University Clinical Research Unit, Vietnam (1)  ·  SK Bioscience Co., Ltd. (1)

Countries

United States (12)  ·  Australia (4)  ·  Austria (4)  ·  Germany (4)  ·  Vietnam (4)  ·  Finland (2)  ·  France (2)  ·  Sweden (2)  ·  Thailand (2)  ·  Canada (1)  ·  India (1)  ·  Nepal (1)  ·  New Zealand (1)  ·  Singapore (1)

Top investigators

Robert Rivard, MD (2)  ·  Thiem D Vu, MD., PhD. (2)  ·  Ulrich Behre, MD (2)  ·  Ajit Rayamajhi, MBBS, MD (1)  ·  Anand Dubey, M.D (1)  ·  Atul Shanker, Dr. (1)  ·  Bakul B. Javadekar, M.D. (1)  ·  Boris Decourt, PhD (1)  ·  Chirgwin K (1)  ·  Christina Forstner, MD (1)  ·  Dominique Costagliola (1)  ·  Hall C (1)

Results publications

PMID 20856164, PMID 20864814, PMID 21148499, PMID 21150279, PMID 21738597, PMID 24884681, PMID 25872531, PMID 25886645, PMID 27686833, PMID 27815383, PMID 28296863, PMID 28403842, PMID 30801037, PMID 32728481, PMID 33899755, PMID 34452033, PMID 34581270, PMID 35101266

NIH funding

2005 (1), K01AG047279 (1), R01AG059008 (1)